# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 13D**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 1)\*

**Concentra Group Holdings Parent, Inc.** 

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

20603L102

(CUSIP Number)

Timothy F. Ryan
Concentra Group Holdings Parent, Inc., 5080 Spectrum Drive, Suite 1200W
Addison, TX, 75001
972-364-8000

Stephen M. Leitzell Dechert LLP, 2929 Arch Street Philadelphia, PA, 19104 215-994-2621

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/03/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

# **SCHEDULE 13D**

**CUSIP No.** 20603L102

Name of reporting person

1

Robert A. Ortenzio

| 2  | Check the appropriate box if a member of a Group (See Instructions)                  |                          |
|--|--|--------------------------|
|  | (a) (b)  |                          |
| 3  | SEC use only   |                          |
| 4  | Source of funds (See Instructions)   |                          |
|  | OO   |                          |
|  | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  |                          |
| 5  | The control of legal proceedings is required pursuant to items 2(d) or 2(e)          |                          |
|  | Citizenship or place of organization   |                          |
| 6  | UNITED STATES  |                          |
|  | 1  |                          |
| Number<br>of Shares<br>Beneficial<br>ly Owned<br>by Each<br>Reporting<br>Person<br>With: | 7  | Sole Voting Power        |
|  |  | 5,513,054.00             |
|  | 8  | Shared Voting Power      |
|  |  | 2,734,428.00             |
|  | 9  | Sole Dispositive Power   |
|  |  | 5,513,054.00             |
|  | 10   | Shared Dispositive Power |
|  |  | 2,734,428.00             |
| 11   | Aggregate amount beneficially owned by each reporting person                         |                          |
|  | 8,247,482.00   |                          |
| 12   | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |                          |
|  |  |                          |
| 13   | Percent of class represented by amount in Row (11)                                   |                          |
|  | 6.4 %  |                          |
| 14   | Type of Reporting Person (See Instructions)  |                          |
|  | IN   |                          |

Person:

Comment for Type (Row 13) Based on 128,125,952 shares of the Company's common stock outstanding as of February 19, 2025 a s disclosed on Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on March 3, 2025.

# SCHEDULE 13D

#### Item 1. Security and Issuer

Title of Class of Securities: (a)

Common Stock, par value \$0.01 per share

(b) Name of Issuer:

Concentra Group Holdings Parent, Inc.

Address of Issuer's Principal Executive Offices: (c)

> C/O SELECT MEDICAL CORPORATION, 4714 GETTYSBURG RD., P.O. BOX 2034, MECHANICSBURG, PENNSYLVANIA, 17055.

**Item 1** This amendment No. 1 ("Amendment No. 1") to Schedule 13D is being filed on behalf of Robert A. Ortenzio relating to t Comment: he common stock, par value \$0.01 per share (the "Common Stock"), of Concentra Group Holdings Parent, Inc., a Dela ware corporation. This Amendment No. 1 modifies the original Schedule 13D filed on December 3, 2024 (as amended and supplemented prior to the filing of this Amendment No. 1, the "Schedule 13D") by Robert A. Ortenzio, a citizen of the e United States.

Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings set forth in the Schedule 13D.

Except as specifically amended by this Amendment No. 1 the Schedule 13D is unchanged.

## Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended to add the following information:

On March 3, 2025, the Reporting Person received 1,023,455 shares of Company's common stock from the Rocco A. Ortenzio Separ ate Exempt Descendants Trust. The shares are held by the Rocco A. Ortenzio Separate Descendants Trust FBO Robert A. Ortenzio. There was no consideration paid for such distribution.

## Item 5. Interest in Securities of the Issuer

(a) Sections (a) and (b) of Item 5 of the Schedule 13D is hereby replaced with the following information:

"(a)-(b) The Reporting Person may be deemed to beneficially own an aggregate of 8,247,482 shares of Company common stock. This aggregate represents approximately 6.4% of the shares of Company's common stock outstanding. The Reporting Person may be deemed to have (a) the sole power to vote or direct the vote of and to dispose of or to direct the disposition of 5,513,054 shares of Company common stock and (b) the current shared power to vote or direct the vote of and to dispose of or direct the disposition of 2,73 4,428 shares of the Company's common stock (including 1,032,115 shares of Company's common stock owned of record by the Robert A. Ortenzio Descendants Trust, 1,023,455 shares of Company's common stock owned of record by the Rocco A. Ortenzio Separa to Descendants Trust FBO Robert A. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Bryan A. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Kevin M. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Madeline G. Ortenzio)."

(b) Sections (a) and (b) of Item 5 of the Schedule 13D is hereby replaced with the following information:

"(a)-(b) The Reporting Person may be deemed to beneficially own an aggregate of 8,247,482 shares of Company common stock. This aggregate represents approximately 6.4% of the shares of Company's common stock outstanding. The Reporting Person may be deemed to have (a) the sole power to vote or direct the vote of and to dispose of or to direct the disposition of 5,513,054 shares of Company common stock and (b) the current shared power to vote or direct the vote of and to dispose of or direct the disposition of 2,73 4,428 shares of the Company's common stock (including 1,032,115 shares of Company's common stock owned of record by the Robert A. Ortenzio Descendants Trust, 1,023,455 shares of Company's common stock owned of record by the Rocco A. Ortenzio Separa to Descendants Trust FBO Robert A. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Bryan A. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Kevin M. Ortenzio, 226,286 shares of Company's common stock owned of record by the Robert A. Ortenzio 2014 Trust for Madeline G. Ortenzio)."

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Robert A. Ortenzio

Signature: /s/ Robert A. Ortenzio
Name/Title: Robert A. Ortenzio

Date: 03/04/2025